635 related articles for article (PubMed ID: 30667296)
61. A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: A Bayesian network meta-analysis.
Liu X; Wong CKH; Wu T; Chan WWL; Woo YC; Lam CLK; Lang BHH
World J Surg; 2024 Feb; 48(2):393-407. PubMed ID: 38686801
[TBL] [Abstract][Full Text] [Related]
62. Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study.
Berg G; Michanek A; Holmberg E; Nyström E
J Intern Med; 1996 Feb; 239(2):165-71. PubMed ID: 8568485
[TBL] [Abstract][Full Text] [Related]
63. [The present status of I-131 therapy for Graves' hyperthyroidism in Japan (survey by questionnaire)].
Ikekubo K; Kusakabe K; Kanaya S; Ishikawa N; Nakada K; Mori Y
Kaku Igaku; 2003 Nov; 40(4):457-63. PubMed ID: 14733111
[TBL] [Abstract][Full Text] [Related]
64. Radioiodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America.
Wartofsky L
Thyroid; 1997 Apr; 7(2):213-6. PubMed ID: 9133687
[TBL] [Abstract][Full Text] [Related]
65. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
[TBL] [Abstract][Full Text] [Related]
66. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
67. Epidemiology, management and outcomes of Graves' disease-real life data.
Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP
Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488
[TBL] [Abstract][Full Text] [Related]
68. Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men.
Onimode YA; Dairo DM; Ellmann A
Pan Afr Med J; 2018; 29():48. PubMed ID: 29875930
[TBL] [Abstract][Full Text] [Related]
69. Management of Graves Disease: A Review.
Burch HB; Cooper DS
JAMA; 2015 Dec; 314(23):2544-54. PubMed ID: 26670972
[TBL] [Abstract][Full Text] [Related]
70. 2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease.
Parameswaran R; de Jong MC; Kit JLW; Sek K; Nam TQ; Thang TV; Khue NT; Aye TT; Tun PM; Cole T; Miller JA; Villa M; Khiewvan B; Sirinvaravong S; Sin YL; Muhammad R; Jap TS; Agrawal A; Rajput R; Fernando R; Sumanatilleke M; Suastika K; Shong YK; Lang B; Bartalena L; Yang SP;
Endocrine; 2023 Jan; 79(1):135-142. PubMed ID: 36129592
[TBL] [Abstract][Full Text] [Related]
71. A SURVEY OF CLINICAL PRACTICE PATTERNS IN MANAGEMENT OF GRAVES DISEASE IN THE MIDDLE EAST AND NORTH AFRICA.
Beshyah SA; Khalil AB; Sherif IH; Benbarka MM; Raza SA; Hussein W; Alzahrani AS; Chadli A
Endocr Pract; 2017 Mar; 23(3):299-308. PubMed ID: 27967219
[TBL] [Abstract][Full Text] [Related]
72. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
[TBL] [Abstract][Full Text] [Related]
73. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
74. Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience.
Azizi F
Thyroid; 2020 Oct; 30(10):1451-1457. PubMed ID: 32253999
[No Abstract] [Full Text] [Related]
75. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison.
Walter MA; Christ-Crain M; Müller B; Müller-Brand J
Nuklearmedizin; 2005 Feb; 44(1):33-6. PubMed ID: 15711727
[TBL] [Abstract][Full Text] [Related]
76. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration.
Calegaro JU; De Freitas Gomes E; Bae SH; Ulyssea R; Casulari LA
Panminerva Med; 2000 Dec; 42(4):241-5. PubMed ID: 11294085
[TBL] [Abstract][Full Text] [Related]
77. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy?
Tigas S; Idiculla J; Beckett G; Toft A
Thyroid; 2000 Dec; 10(12):1107-11. PubMed ID: 11201857
[TBL] [Abstract][Full Text] [Related]
78. Surgical treatment of Graves' disease: evidence-based approach.
Stålberg P; Svensson A; Hessman O; Akerström G; Hellman P
World J Surg; 2008 Jul; 32(7):1269-77. PubMed ID: 18327526
[TBL] [Abstract][Full Text] [Related]
79. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
80. A survey of the young person's experience of Graves' disease and its management.
Lane LC; Rankin J; Cheetham T
Clin Endocrinol (Oxf); 2021 Feb; 94(2):330-340. PubMed ID: 33128233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
